FC
LGND icon

FORA Capital’s Ligand Pharmaceuticals LGND Stock Holding History

FORA Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,922
Closed -$337K – 527
2025
Q4 		$337K Buy
+1,922
New +$369K 0.04% 351
2021
Q2 		– Sell
-378
Closed -$36K – 1029
2021
Q1 		$36K Buy
+378
New +$35.7K 0.01% 597
2020
Q3 		– Sell
-1,496
Closed -$104K – 839
2020
Q2 		$104K Buy
+1,496
New +$94.8K 0.04% 484

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

FORA Capital's LGND Position: Q1 2026 in Review

FORA Capital sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 1,922 shares — an estimated $337K sold.

FORA Capital first reported a position in LGND in Q2 2020 and held it in 3 quarters. The position peaked at $337K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • FORA Capital reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • FORA Capital sold 1,922 Ligand Pharmaceuticals shares in Q1 2026, an estimated $337K.
  • FORA Capital first reported a position in Ligand Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • FORA Capital's Ligand Pharmaceuticals position peaked at $337K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.